Newsbenzinga
Arvinas Says ARV-102 Shows Dose-Dependent Eye Movement Improvement In 24-Patient Phase 1 Parkinson's Trial Not Designed To Assess Efficacy
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…